atorvastatin has been researched along with sorafenib in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, Y; Dai, F; Gu, T; Jiang, H; Li, K; Liang, Z; Liu, Y; She, J; Tang, L; Zhan, Z; Zhou, X | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Dabora, SL; Lee, N; Messina, MP; Nobil, AM; Rauktys, AE; Woodrum, CL | 1 |
| Chang, LL; Chen, Y; Chen, ZB; He, QJ; Hu, Y; Lin, WK; Lou, JS; Wan, ZQ; Wang, DD; Yang, B; Ye, S; Ying, MD; Zhou, TY; Zhou, YL; Zhu, H; Zhuang, LH | 1 |
| Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S | 1 |
2 review(s) available for atorvastatin and sorafenib
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
1 trial(s) available for atorvastatin and sorafenib
| Article | Year |
|---|---|
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
Topics: Antineoplastic Agents; Atorvastatin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2022 |
3 other study(ies) available for atorvastatin and sorafenib
| Article | Year |
|---|---|
LXR-Mediated Regulation of Marine-Derived Piericidins Aggravates High-Cholesterol Diet-Induced Cholesterol Metabolism Disorder in Mice.
Topics: Animals; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Dose-Response Relationship, Drug; Hep G2 Cells; Humans; Liver X Receptors; Male; Mice; Mice, Inbred C57BL; Molecular Structure; Pericarditis; Structure-Activity Relationship; Tumor Cells, Cultured | 2021 |
Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Topics: Animals; Atorvastatin; Benzenesulfonates; Cystadenoma; Disease Models, Animal; Doxycycline; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Heptanoic Acids; Immunosuppressive Agents; Interferon-gamma; Kidney Neoplasms; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Neoplasms, Experimental; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sirolimus; Sorafenib; Survival Analysis; Treatment Outcome; Tuberous Sclerosis; Tuberous Sclerosis Complex 2 Protein; Tumor Burden; Tumor Suppressor Proteins | 2009 |
Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Topics: Adaptor Proteins, Signal Transducing; Animals; Apoptosis; Atorvastatin; Carcinoma, Hepatocellular; Cell Hypoxia; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver Neoplasms; Mice, Nude; Niacinamide; Phenylurea Compounds; Phosphoproteins; Prognosis; Protein Transport; Sorafenib; Transcription Factors; Xenograft Model Antitumor Assays; YAP-Signaling Proteins | 2016 |